Lenalidomide (Revlimid)

From HemOnc.org - A Hematology Oncology Wiki
Jump to: navigation, search

General information

Class/mechanism: Second-generation immunomodulatory drug (IMiD) similar to Thalidomide (Thalomid); mechanism not fully understood. Lenalidomide's mechanism may involve immunomodulatory, antiinflammatory, and antiangiogenic effects and suppression of tumor necrosis factor-alpha (TNF-α) from peripheral blood mononuclear cells. It has been observed to inhibit cells with the 5q deletion in myelodysplastic syndromes. It has also been seen in vitro to inhibit cyclooxygenase-2 (COX-2) expression, but not COX-1.[1][2][3][4]
Route: PO
Extravasation: n/a

For conciseness and simplicity, HemOnc.org currently will focus on treatment regimens and not list information such as: renal/hepatic dose adjustments, metabolism (including CYP450), excretion, monitoring parameters (although this will be considered for checklists), or manufacturer. Instead, for the most current information, please refer to your preferred pharmacopeias such as Micromedex, Lexicomp, UpToDate (courtesy of Lexicomp), or the prescribing information.[1]

Diseases for which it is used

Patient drug information

History of changes in FDA indication

Also known as

  • Code names: CC-5013, IMiD-1, NSC-703813
  • Brand names: Kabillon, Lenalid, Lenangio, Lenmid, Lenome, Lenzest, MyeloSar, Revlimid

References

  1. 1.0 1.1 1.2 1.3 1.4 1.5 Lenalidomide (Revlimid) package insert
  2. Lenalidomide (Revlimid) package insert (locally hosted backup)
  3. Revlimid manufacturer's site
  4. 4.0 4.1 Revlimid REMS program
  5. Lenalidomide (Revlimid) patient medication guide
  6. Lenalidomide (Revlimid) patient drug information (Chemocare)
  7. Lenalidomide (Revlimid) patient drug information (UpToDate)